Carol Yepes/Moment via Getty Images
Cerevel Therapeutics (NASDAQ:CERE) said it and AbbVie (NYSE:ABBV) have both received Second Requests from the FTC for additional information regarding their planned $8.7B merger.
Cerevel said the Second Request will extend the Hart-Scott-Rodino Act waiting period for the closing to 30 days after the companies have substantially complied with the request, unless the companies choose to extend or the period is terminated earlier by the FTC.
Despite the Second Request, Cerevel said it still expects the deal to close in mid-2024. The company added that Cerevel shareholders approved the merger in a special meeting held on Feb. 16, according to an SEC filing.
In early December, AbbVie announced plans to acquire Cerevel for $45 per share, or roughly $8.7B, in cash.